• Acadia Pharmaceuticals Inc., of San Diego, said the FDA cleared schizophrenia drug AM-831 to begin a Phase I trial. AM-831 is a small molecule that combines muscarinic m1 partial agonism with dopamine D2 and serotonin 5-HT2A antagonism. The drug was discovered by Acadia and developed in collaboration with Tokyo-based Meiji Seika Kaisha Ltd., under the companies' 2009 antipsychotic deal for Asian territories.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter